March 25, 2025‌ – A delegation led by Bian Yijun, First-grade Researcher of the Ningbo Municipal Bureau of Economy and Information Technology, conducted a research visit to Zhejiang Tianyuan Biotechnology Co., Ltd. The company’s leadership, including Chairman Huang Bisheng, Group Administrative Director Zhu Youwu, Executive Vice General Manager Zhu Pengcheng, and Dr. Chen Junjie, Director of the Cell Research Laboratory, warmly received the delegation and accompanied them on a tour.

     The delegation first visited Tianyuan Biotechnology’s Life Science Exhibition Hall, which showcased the company’s development history, scientific achievements, and future plans. During the tour, Chairman Huang Bisheng elaborated on the company’s innovative accomplishments in biotechnology. These include the establishment of ‌China’s first Metabolic Immunology Monitoring Joint Laboratory‌ in collaboration with the National Health Commission, positioning the company as a ‌formulator of national immunity standards‌, as well as collaborative projects such as the ‌Precision Tumor Detection Research Center‌ and the ‌Biopharmaceutical Innovation Institute‌ co-founded with Ningbo University. The delegation also showed keen interest in the company’s pioneering initiatives, such as the ‌world’s first Perinatal Mesenchymal Stem Cell HLA Typing Bank‌, cutting-edge research on ‌iPS-induced pluripotent stem cells‌, and advancements in ‌suspension culture technologies for stem cell seed cells‌.

     Following the tour, both parties held an in-depth development symposium. At the meeting, Administrative Director Zhu Youwu provided a detailed report on the company’s R&D, production, and market expansion efforts in the biopharmaceutical sector. The delegation highly commended Tianyuan Biotechnology’s contributions to advancing the biopharmaceutical industry. Researcher Bian Yijun emphasized that as a leading enterprise in Ningbo’s biopharmaceutical sector, Tianyuan Biotechnology has achieved remarkable progress in technological innovation, product development, and industry-university-research collaboration, making significant contributions to the industry’s growth in the region. He encouraged the company to further increase R&D investment, strengthen partnerships with universities and research institutions, and enhance its core competitiveness to inject new momentum into the high-quality development of Ningbo’s biopharmaceutical industry.

     Chairman Huang Bisheng outlined the company’s future vision during the symposium. He stated that Tianyuan Biotechnology will continue to prioritize scientific innovation, expand R&D investment in biopharmaceuticals, diversify its business domains, and elevate its comprehensive capabilities. The company will actively align with national and municipal policies, foster collaboration with stakeholders, and jointly propel the growth of the biopharmaceutical industry. Chairman Huang reaffirmed the company’s mission to ‌“Converge the Essence of Science, Safeguard Human Health”‌ and its commitment to delivering superior healthcare solutions to society.

This inspection and guidance from the Ningbo Municipal Bureau of Economy and Information Technology not only provided valuable insights for Tianyuan Biotechnology but also reinforced the company’s confidence in its development trajectory. With collective efforts, Tianyuan Biotechnology is poised to embrace broader prospects and contribute even more substantially to the advancement of Ningbo’s biopharmaceutical industry.